Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
There are now five targeted therapies for the most common type of liver cancer.
Do you know your liver cancer risk?
Tenofovir was associated with a lower risk of hepatocellular carcinoma, but this might be related to other factors as well.
Study finds that having more diverse gut bacteria was associated with better response to immunotherapy.
Cabometyx is the third liver cancer drug approved in the past six months.
People with HIV who have higher viral load and worse immune function appear to be at higher risk for hepatocellular carcinoma.
A study found that people who had the largest increase in whole grain lowered their liver cancer risk by nearly 40 percent.
Seventy percent of liver cancer patients had either a partial response or stable disease.
Median progression-free survival 5.2 months in cabozantinib arm versus 1.9 months in placebo arms.
Rick George credits his spiritual life with seeing him through multiple health crises, including liver cancer.
Half of people with worse liver function responded well to immunotherapy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.